Browsing Category
Pharma Industry News
4747 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Wockhardt delivers strong FY25 EBITDA, but net loss persists amid US restructuring drag
Wockhardt posts a 67% EBITDA jump in FY25, but Q4 PAT remains negative. Find out how novel antibiotics like Zaynich and Miqnaf are shaping investor sentiment.
RYALTRIS: Glenmark’s quiet blockbuster? A 45-market launch strategy explained
RYALTRIS is Glenmark’s global allergy brand launched in 45+ countries. Explore how it’s reshaping the firm’s branded strategy and global revenue mix.
How Eli Lilly’s $1bn SiteOne deal strengthens its bid to lead in non-opioid pain therapies
Eli Lilly to acquire SiteOne Therapeutics for up to $1B, betting on STC-004 to redefine non-opioid pain treatment. Read why investors and analysts are watching.
Tonix Pharmaceuticals stock watch: Is this 28% jump the start of a biotech rebound or a speculative spike?
Tonix Pharmaceuticals stock soared 28% on May 27. Is it a biotech comeback or just a short squeeze? Read the deep dive on TNXP’s pipeline, sentiment, and funding risks.
How 3SBio became China’s most watched biotech firm after the Pfizer deal
3SBio is now at the center of global oncology focus after licensing SSGJ-707 to Pfizer. Explore what’s driving its stock surge and strategic ascent.
Pharma stock watch: Are Indian midcaps like Glenmark better positioned than the giants?
Are Indian midcap pharma stocks like Glenmark set to outperform giants like Sun and Cipla? Explore 2025 trends, biotech bets, and market sentiment shifts.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
PRX012 Alzheimer’s trial: Can Prothena rebound from birtamimab setback?
After a major clinical failure, Prothena shifts focus to Alzheimer’s drug PRX012. Will this next trial restore investor confidence?
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight
Glenmark Pharmaceuticals’ ISB 2001 gets FDA Fast Track for multiple myeloma. Explore how this could redefine its biotech future and rival global oncology innovators.